Ten-year evaluation of a neonatal screening program for congenital adrenal hyperplasia;Avaliação de dez anos de um programa de triagem neonatal para hiperplasia adrenal congênita

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 7, 2014, Pages 765-771

  Nascimento, Marilza Leal ^a   Cristiano, Anísia Nhelety Baptista ^b   Campos, Tatiane de ^a   Ohira, Masanao ^b   Cechinel, Edson ^a   Simoni, Genoir ^a   van de Sande Juliana, Lee ^a   Linhares, Rose Marie Muller ^a   Silva, Paulo Cesar Alves da ^a  

^a HOSPITAL INFANTIL JOANA DE GUSMÃO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

17 hydroxyprogesterone; 21 hydroxylase deficiency; Congenital adrenal hyperplasia; Neonatal screening

Indexed keywords

HYDROXYPROGESTERONE;

ADRENAL HYPERPLASIA, CONGENITAL; ANIMAL; BIRTH WEIGHT; BLOOD; BRAZIL; CLASSIFICATION; FEMALE; HEEL; HUMAN; INCIDENCE; MALE; NEWBORN; NEWBORN SCREENING; PHYSIOLOGY; PROGRAM EVALUATION; RETROSPECTIVE STUDY; UTILIZATION;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; ANIMALS; BIRTH WEIGHT; BRAZIL; FEMALE; HEEL; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PROGRAM EVALUATION; RETROSPECTIVE STUDIES;

EID: 84908373884     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000003310     Document Type: Article

References (33)

1. Krone N, Dhir V, Ivison HE, Arlt W. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf). 2007;66:162-72.
2. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125-36.
3. Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update. 2004;10(6):469-85.
4. Forest MG, Tardy V, Nicolino M, David M, Morel Y. 21-Hydroxylase deficiency: an exemplary model of the contribution of molecular biology in the understanding and management of the disease. Ann Endocrinol (Paris). 2005;66(3):225-32.
5. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133-60.
6. Working Group on Neonatal Screening of the European Society for Pediatric Endocrinology. Procedure for neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res. 2001;55:201-5.
7. Honour JW, Torresani T. Evaluation of neonatal screening for congenital adrenal hyperplasia. Horm Res. 2001;55:206-11.
8. Nordenström A, Ahmed S, Jones J, Coleman M, Price DA, Clayton PE, et al. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm Res. 2005;63:22-8.
9. White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009;5:490-8.
10. Cavarzere P, Camilot M, Teofoli F, Tatò L. Neonatal screening for congenital adrenal hyperplasia in North-Eastern Italy: a report three years into the program. Horm Res. 2005;63(4):180-6.
11. Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening forcongenital adrenal hyperplasia? Horm Res. 2007;67(6):284-91.
12. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45:1003-8.
13. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21:245-91.
14. White PC, New MI. Genetic basis of endocrine disease: congenital adrenal hyperplasis due to 21-hydroxylase. J Clin Endocrinol Metab. 1992;74:6-11.
15. Thil’en A, Nordenström A, Hagenfeldt L, von Döbeln U, Guthenberg C, Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics. 1998;101(4):E11.
16. Banco de Dados do Sistema Único de Saúde. Nascidos Vivos-Santa Catarina [Internet] 2012. Available at: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sinasc/cnv/nvSC.def. Accessed on: Jul 15, 2012.
17. Instituto Brasileiro de Geografia e Estatística. Censo Demográfico 2010 [Internet] 2012. Accessed on: Fev 11, 2012. Available at: http://www.censo2010.ibge.gov.br.
18. Borrajo G. Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis. 2007;30(4):466-81.
19. Nascimento ML. Situação atual da triagem neonatal para hipotireoidismo congênito: críticas e perspectivas. Arq Bras Endocrinol Metab. 2011;55(8):528-33.
20. Silveira EL, dos Santos EP, Bachega TA, van der Linden Nader I, Gross JL, Elnecave RH. The actual incidence of congenital adrenal hyperplasia in Brazil may not be as high as inferred--an estimate based on a public neonatal screening program in the state of Goiás. J Pediatr Endocrinol Metab. 2008;21(5):455-60.
21. Barra CB, Silva IN, Pezzuti IL, Januário JN. Triagem neonatal para hiperplasia adrenal congênita. Rev Assoc Med Bras. 2012;58(4):459-64.
22. Gruneiro-Papendieck L, Chiesa A, Mendez V, Prieto L. Neonatal screening for congenital adrenal hyperplasia: experience and results in Argentina. J Clin Endocrinol Metab. 2008;21:73-8.
23. Pang S, Murphey W, Levine LS, Spence DA, Leon A, La Franchi S, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab. 1982;55:413-20.
24. van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2004;151 Suppl 3:U71-5.
25. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117:1915-21.
26. Fernández BH, Fernández ME, Íñiguez ED, Zubicaray BE, Martín MBR, Arnao MDR, et al. Neonatal screening for congenital adrenal hyperplasia: transitory elevation of 17-hydroxyprogesterone. J Clin Endocrinol Metab. 2011;24(3-4):155-62.
27. Alves CAD, Balesteri V, Toralles MBP. Triagem neonatal para hiperplasia adrenal congênita: considerações sobre a elevação transitória da 17-hidroxiprogesterona. RBPS. 2006;19(4):203-8.
28. Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, Oliveira E, et al. Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia. Arq Bras Endocrinol Metab. 2011;55(8):632-7.
29. Van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, Wit JM, et al. Cutoff levels of 17-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab. 2005;90:3904-7.
30. Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics. 1996;98(3 Pt 1):362-7.
31. Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley DH, Blackett PR, et al. Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med. 1999;153:1272-8.
32. Therrell Jr BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 1998;101:583-90.
33. New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91:4205-14.